The trial is taking place at:
R

Rochester Clinical Research | Rochester, NY

Veeva-enabled site

A Chronic Weight Management Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Lilly logo

Lilly

Status and phase

Enrolling
Phase 2

Conditions

Overweight
Obesity

Treatments

Drug: LY3305677
Drug: LY3841136
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT06143956
18685
W8M-MC-CWMM (Other Identifier)

Details and patient eligibility

About

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.

Full description

The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The results for the CWMM screening record will be reported when all the ISA's complete.

Enrollment

390 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Have a Body Mass Index (BMI) ≥30 kilograms per square meter (kg/m²) Have a BMI ≥27 kg/m²and <30 kg/m² with at least one of the following weight-related comorbidities: hypertension: on blood pressure (BP)-lowering medication. dyslipidemia: on lipid-lowering medication cardiovascular (CV) disease: for example, ischemic CV disease, New York Heart Association (NYHA) Functional Classification Class I or II heart failure. obstructive sleep apnea Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss.

Exclusion criteria

Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening. Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma. Have poorly controlled hypertension. Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease. Have any of the following cardiovascular conditions within 3 months prior to screening: acute myocardial infarction cerebrovascular accident (stroke) unstable angina, or hospitalization due to congestive heart failure. Have a history of symptomatic gallbladder disease within the past 2 years. Have a lifetime history of suicide attempts.

Trial design

Primary purpose

Screening

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

390 participants in 2 patient groups

LY3305677 Obesity ISA OXA1
Experimental group
Description:
Participants will receive LY3305677 or placebo subcutaneously (SC). Each ISA will detail the intervention specific analysis.
Treatment:
Drug: Placebo
Drug: LY3305677
LY3841136 Obesity ISA LAA1
Experimental group
Description:
Participants will receive LY3841136 or placebo SC. Each ISA will detail the intervention specific analysis.
Treatment:
Drug: Placebo
Drug: LY3841136

Trial contacts and locations

41

Loading...

Central trial contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems